Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Michelmersh following interim results

(Sharecast News) - Analysts at Berenberg lowered their target price on brick maker Michelmersh from 170p to 150p on Tuesday after the group published its H125 results earlier in the morning. Michelmersh stated that overall, trading has continued to be "broadly resilient" amid a tough market backdrop, although certain factors have weighed on progress, leaving management to now guide FY25 performance to be in line with FY24.

Berenberg said the key points from Michelmersh's statement were that overall UK despatch volumes have shown some recovery in the period, that pricing, production delays at the Carlton plant and a tough Belgian market had weighed, and that the period ended with £1.5m net cash, continuing to leave the business with a strong balance sheet.

The German bank, which has a 'buy' rating on the stock, updated its numbers post-results and noted a 13-16% reduction in adjusted underlying earnings across the forecast period, moving the price target down.

However, Berenberg said the stock continues to provide operationally geared exposure to a recovery in building material volumes.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.